Clinical trials
Completed Phase 3 Myeloproliferative Disorders trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 6 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2014 | 5 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2023 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 37 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alliance for Clinical Trials in Oncology | 4 |
| AOP Orphan Pharmaceuticals AG | 3 |
| Fred Hutchinson Cancer Center | 3 |
| Case Comprehensive Cancer Center | 2 |
| Children's Oncology Group | 2 |
| Novartis Pharmaceuticals | 2 |
| Vanderbilt-Ingram Cancer Center | 2 |
| Aronex Pharmaceuticals | 1 |
| Celgene | 1 |
| Dartmouth-Hitchcock Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myeloproliferative Disorders | 37 |
| Myelodysplastic Syndromes | 19 |
| Leukemia | 18 |
| Leukemia, Myeloid, Acute | 17 |
| Multiple Myeloma | 17 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 17 |
| Primary Myelofibrosis | 17 |
| Hodgkin Disease | 16 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 16 |
| Leukemia, Myelomonocytic, Chronic | 16 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.